VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

被引：43
作者：
Carbone, David P. [1 ]
Salmon, J. Stuart [3 ]
Billheimer, Dean [2 ]
Chen, Heidi [1 ]
Sandler, Alan [1 ]
Roder, Heinrich [4 ]
Roder, Joanna [4 ]
Tsypin, Maxim
Herbst, Roy S. [5 ]
Tsao, Anne S. [5 ]
Tran, Hai T. [5 ]
Dang, Thao P. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Carolinas Hematol Oncol Associates, Charlotte, NC USA
[4] Biodesix, Steamboat Springs, CO USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LUNG CANCER | 2010年 / 69卷 / 03期
关键词：
Lung cancer; Erlotinib; Bevacizumab; Serum biomarker; Proteomics; Personalized therapy; ENDOTHELIAL GROWTH-FACTOR; MASS-SPECTROMETRY; CHEMOTHERAPY; COMBINATION; RECURRENT;
D O I：
10.1016/j.lungcan.2009.11.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat (R)) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat (R) could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：337 / 340
页数：4
相关论文
共 50 条
[41]   Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib [J].
Ishii, Hidenobu ;
Azuma, Koichi ;
Yamada, Kazuhiko ;
Kinoshita, Takashi ;
Imamura, Youhei ;
Hoshino, Tomoaki .
ONCOLOGY LETTERS, 2014, 8 (06) :2699-2704
[42]   Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) [J].
Cohen, Martin H. ;
Johnson, John R. ;
Chattopadhyay, Somesh ;
Tang, Shenghui ;
Justice, Robert ;
Sridhara, Rajeshwari ;
Pazdur, Richard .
ONCOLOGIST, 2010, 15 (12) :1344-1351
[43]   Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics [J].
Sotgia, Federica ;
Lisanti, Michael P. .
ONCOTARGET, 2017, 8 (40) :68095-68107
[44]   PHASE II STUDY OF BIWEEKLY IRINOTECAN PLUS BEVACIZUMAB IN HEAVILY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) [J].
Cardona, Andres F. ;
Arrieta, Oscar ;
Cuello, Mauricio ;
Corrales, Luis ;
Vargas, Carlos ;
Martin, Claudio ;
Carranza, Hernan ;
Otero, Jorge M. ;
Katherine Rodriguez, July ;
Mas, Luis ;
Archila, Pilar ;
Bramuglia, Guillermo ;
Pastran, Zulay ;
Curcio, Elizabeth ;
Rojas, Leonardo ;
Bernal, Laura ;
Campos Parra, Alma D. ;
Giannikopoulos, Petros ;
Rosell, Rafael .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S881-S882
[45]   Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis [J].
Abdel-Rahman, Omar ;
Ahmed, Hoda ;
ElHalawani, Hesham .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (02) :223-234
[46]   EFFECT OF ERLOTINIB COMBINED WITH BEVACIZUMAB ON IMMUNE RESPONSE AND SERUM TUMOR MARKERS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER [J].
Wang, Jiang ;
Xiong, Chunyan .
ACTA MEDICA MEDITERRANEA, 2023, 39 (01) :169-173
[47]   Erlotinib in non-small cell lung cancer: a review [J].
Blackhall, FH ;
Rehman, S ;
Thatcher, N .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) :995-1002
[48]   Erlotinib in the treatment of non-small cell lung cancer [J].
Brown, Ewan R. ;
Shepherd, Frances A. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) :767-775
[49]   Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer A systematic review and meta-analysis [J].
Zhou, Kenan ;
Zhao, Shishun ;
Guo, Wenlai ;
Ding, Lei .
MEDICINE, 2020, 99 (03)
[50]   Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer [J].
Kaburagi, Takayuki ;
Satoh, Hiroaki ;
Hayashihara, Kenji ;
Endo, Takeshi ;
Hizawa, Nobuyuki ;
Kurishima, Koichi ;
Nishimura, Yoshihiro ;
Hashimoto, Toshio ;
Nakamura, Hiroyuki ;
Kishi, Koji ;
Inagaki, Masaharu ;
Nawa, Takeshi ;
Ichimura, Hideo ;
Ishikawa, Hiroichi ;
Kagohashi, Katsunori ;
Fukuoka, Toshihiko ;
Shinohara, Yoko ;
Kamiyama, Koichi ;
Sato, Yukio ;
Sakai, Mitsuaki ;
Matsumura, Takeshi ;
Uchiumi, Keiko ;
Furukawa, Kinya .
ONCOLOGY LETTERS, 2013, 5 (02) :435-439
12345